Research progress on the role of ganglioside GD2 in triple-negative breast cancer

doi:10.3969/j.issn.1009-976X.2025.02.008

Abstract

Abstract: Triple-negative breast cancer is a subtype of breast cancer with stronginvasiveness and poor prognosis. At the same time, it has found that ganglioside GD2 is abnormally expressed in many malignant tumors. In recent years, the research on GD2 in triple negative breast cancer has made some progress. It was found that GD2 was highly expressed on the surface of triple negative breast cancer cells, which was closely related to the proliferation, invasion and metastasis of tumor cells. GD2 may be a potential therapeutic target for triple negative breast cancer. It is believed that the research around GD2 will open up a new way for the prevention and treatment of triple negative breast cancer. This article reviews the biological characteristics of GD2 and the research progress in triple-negative breast cancer.

Key words: triple negative breast cancer, breast tumor stem cells, ganglioside, GD2, immunotherapy

摘要： 三阴性乳腺癌是乳腺癌中侵袭性强、预后较差的一种亚型,同时,研究发现神经节苷脂GD2在多种恶性肿瘤中异常表达。近年来,针对GD2在三阴性乳腺癌中的研究取得了一定进展,研究发现GD2在三阴性乳腺癌细胞表面存在高表达现象,且与肿瘤细胞增殖、侵袭和转移密切相关,因此GD2可能成为三阴性乳腺癌潜在的治疗靶点。相信围绕GD2展开的研究将为三阴性乳腺癌防治开辟新的道路。本文围绕GD2的生物学特性及其在三阴性乳腺癌中研究进展展开以综述。

关键词: 三阴性乳腺癌, 乳腺肿瘤干细胞, 神经节苷脂, GD2, 免疫治疗

CLC Number:

R737.9

WEI Tian-tian, SUN Zhu-sheng. Research progress on the role of ganglioside GD2 in triple-negative breast cancer[J]. Lingnan Modern Clinics In Surgery, 2025, 25(02): 135-139.

魏恬恬, 孙祝生. 神经节苷脂GD2在三阴性乳腺癌中作用的研究进展[J]. 岭南现代临床外科, 2025, 25(02): 135-139.

References

[1] Svennerholm L.Chromatographic Separation Of Human Brain Gangliosides[J]. J Neurochem, 1963, 10: 613-623.
[2] Liu J, Zheng X, Pang X, et al.Ganglioside GD3 synthase (GD3S), a novel cancer drug target[J]. Acta Pharm Sin B, 2018, 8(5): 713-720.
[3] 杨柳, 李本尚, 陈静. 以神经节苷脂GD2为靶点细胞免疫治疗神经母细胞瘤的研究进展[J]. 中华儿科杂志, 2016, 54(6): 476-478.
[4] Mokbel K.GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target[J]. Cancer Genomics Proteomics, 2024, 21(6): 549-556.
[5] Groux-Degroote S, Guérardel Y, Delannoy P.Gangliosides: Structures, Biosynthesis, Analysis, and Roles in Cancer[J]. Chembiochem, 2017, 18(13): 1146-1154.
[6] Wei X, Li S, Wang Y.Expression of GD2 and GD3 in peripheral neuroblastic tumors[J]. Indian J Pathol Microbiol, 2025, 68(1):17-22
[7] Imamura A, Ando H, Ishida H.Chemical Synthesis of Gangliosides[J]. Methods Mol Biol, 2023, 2613: 89-100.
[8] Tibbetts R, Yeo KK, Muthugounder S, et al.Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance[J]. Cancer Immunol Immunother, 2022, 71(1): 153-164.
[9] Pershina O, Ermakova N, Pakhomova A, et al.Cancer Stem Cells and Somatic Stem Cells as Potential New Drug Targets, Prognosis Markers, and Therapy Efficacy Predictors in Breast Cancer Treatment[J]. Biomedicines, 2021, 9(9): 1223.
[10] Shah MA, Shitara K, Lordick F, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[J]. Clin Cancer Res, 2022, 28(17): of1-of9.
[11] Romaniuk-Drapa?a A, Totoń E, Taube M, et al. Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies[J]. Cancers (Basel), 2024, 16(13): 2481.
[12] Li W, Ma H, Zhang J, et al.Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis[J]. Sci Rep, 2017, 7(1): 13856.
[13] Ordaz-Ramos A, Tellez-Jimenez O, Vazquez-Santillan K.Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications[J]. Front Cell Dev Biol, 2023, 11: 1221175.
[14] Flores-Huerta N, Silva-CázaresMB, Arriaga-PizanoLA, et al. LncRNAs and microRNAs as Essential Regulators of Stemness in Breast Cancer Stem Cells[J]. Biomolecules, 2021, 11(3): 380.
[15] Zheng Q, Zhang M, Zhou F, et al.The Breast Cancer Stem Cells Traits and Drug Resistance[J]. Front Pharmacol, 2020, 11: 599965.
[16] ElbaiomyMA, Akl T, Atwan N, et al. Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients[J]. J Oncol, 2020, 2020: 2561726.
[17] Salvadori G, Zanardi F, Iannelli F, et al. Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape[J]. Cell Metab, 2021, 33(11): 2247-2259. e6.
[18] BattulaVL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis[J]. J Clin Invest, 2012, 122(6): 2066-2078.
[19] Nguyen K, Battula VL.Targeting NFκB signaling in GD2(+) BCSCs[J]. Aging (Albany NY), 2017, 9(8): 1847-1848.
[20] Corti C, Venetis K, Sajjadi E, et al.CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress[J]. Expert Opin Investig Drugs, 2022, 31(6): 593-605.
[21] 齐倩, 郝辉, 徐伟, 等. 神经节苷脂GD2对人三阴性乳腺癌细胞增殖和凋亡的影响[J]. 解剖科学进展, 2024, 30(06): 614-616.
[22] Liang YJ, Wang CY, Wang IA, et al.Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype[J]. Oncotarget, 2017, 8(29): 47454-47473.
[23] Zhang L, Chen W, Liu S, et al.Targeting Breast Cancer Stem Cells[J]. Int J Biol Sci, 2023, 19(2): 552-570.
[24] Ly S, Anand V, El-Dana F, et al.Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells[J]. J Immunother Cancer, 2021, 9(3): e001197.
[25] Obidiro O, Battogtokh G, Akala EO.Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook[J]. Pharmaceutics, 2023, 15(7): 1796.
[26] Erber R, Kailayangiri S, Huebner H, et al.Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes[J]. Cancers (Basel), 2021, 13(21): 5577.
[27] Higashi C, Saito K, Kozuka Y, et al.Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer[J]. Anticancer Res, 2023, 43(9): 4045-4053.
[28] Tarantino P, Corti C, Schmid P, et al.Immunotherapy for early triple negative breast cancer: research agenda for the next decade[J]. NPJ Breast Cancer, 2022, 8(1): 23.
[29] Sajjadi E, Venetis K, Scatena C, et al.Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?[J]. Ecancermedicalscience, 2020, 14: 1150.
[30] Geng P, Chi Y, Yuan Y, et al.Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer[J]. Front Cell Dev Biol, 2023, 11: 1158539.
[31] Gargett T, Truong NTH, Gardam B, et al.Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers[J]. J Immunother Cancer, 2024, 12(5):e008659.
[32] Seitz CM, Schroeder S, Knopf P, et al.GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells[J]. Oncoimmunology, 2020, 9(1): 1683345.
[33] Philippova J, Shevchenko J, Sennikov S.GD2-targeting therapy: a comparative analysis of approaches and promising directions[J]. Front Immunol, 2024, 15: 1371345.